Claims for Patent: 11,083,712

Summary for Patent: 11,083,712

Title:	Low concentration delivery of an ergoline derivative for treatment of a headache
Abstract:	Provided are ergoline derivative containing medicaments disposed within a preassembled, prefilled, single-use delivery device, methods for administering a medicament using a preassembled, prefilled, single-use delivery device, and systems or kits that contain one or more preassembled, prefilled, single-use devices and user instructions, such as for treatment of a migraine or other headache.
Inventor(s):	Ralph Solarski, Robert Edward Malone
Assignee:	Relevale Inc
Application Number:	US16/359,313
Patent Claims:	1. A method of treating a headache in a person, comprising administering an ergoline derivative medicament using preassembled, prefilled, single use delivery device, the method comprising: placing the delivery device against an injection site; actuating a trigger mechanism of the delivery device, wherein the trigger mechanism, when actuated, causes a dosing mechanism of the delivery device to advance the syringe and the injection needle, and to discharge the medicament though the injection needle; and maintaining the delivery device against the injection site, while the injection needle penetrates the injection site, and the medicament contained in the syringe is injected though the injection needle into the injection site; wherein the medicament comprises a concentration range of about 0.3 mg/mL to about 1.5 mg/mL of an ergoline derivative. 2. The method of claim 1, wherein the dosing mechanism of the delivery device is not adjustable by the user. 3. The method of claim 1, wherein a dose amount delivered by the delivery device is not adjustable by the user. 4. The method of claim 1, wherein the ergoline derivative medicament comprises dihydroergotamine or a pharmaceutically acceptable salt thereof. 5. The method of claim 4, wherein the ergoline derivative medicament comprises dihydroergotamine and/or dihydroergotamine mesylate. 6. The method of claim 5, wherein the concentration of the ergoline derivative is about 1 mg/mL. 7. The method of claim 5, wherein a dose of the ergoline derivative ranges from about 0.5 mg to 3 mg. 8. The method of claim 5, wherein the delivery device is an autoinjector and the medicament is self-administered while the person is experiencing an onset of a headache. 9. The method of claim 8, wherein the headache comprises a migraine headache, a tension-type headache, or a cluster headache. 10. The method of claim 8, wherein the headache comprises hemicrania continua, new daily persistent headache, a post-traumatic headache, or a medication overuse headache. 11. The method of claim 8, wherein the injection needle has a length sufficient for subcutaneous injection, with a 25-30 gauge. 12. The method of claim 11, wherein the medicament is administered within 2 minutes or less after the onset of the headache. 13. The method of claim 11, wherein the medicament is administered within 5 minutes or less after the onset of the headache. 14. The method of claim 11, wherein the medicament is administered within 10 minutes or less after the onset of the headache. 15. The method of claim 11, wherein the medicament is administered within 20 minutes or less after the onset of the headache. 16. The method of claim 8, further comprising removing a safety cap from the auto-injector device. 17. The method of claim 16, further comprising removing the safety cap from the auto-injector device predominately using gross motor movements. 18. The method of claim 17, wherein removing the safety cap comprises gripping the safety cap with the thenar space of one hand and gripping the handle with another hand, and pulling the safety cap off of the cartridge, the safety cap comprising a flared cap with a narrow portion configured to fit comfortably into the thenar space of a user's hand. 19. The method of claim 17, wherein removing the safety cap comprises gripping the safety cap in an armpit (axilla), elbow pit (cubital fossa), or knee pit (popliteal fossa) and pulling on the handle with one or both hands, the safety cap comprising a flared portion configured to facilitate the gripping. 20. The method of claim 17, wherein removing the safety cap comprises wedging the safety cap between a posterior thigh of the user's leg and a surface of a seat and pulling on the handle with one or both hands, the weight of the user's leg gripping the safety cap while the person pulls on the handle, the safety cap comprising a flared portion to facilitate the wedging. 21. The method of claim 8, wherein the dosing mechanism comprises a piston rod retained in an armed position and keeping a spring under compression, the piston rod being in contact with a plunger of the syringe, and when the trigger is actuated, the piston rod is released from its retainer and the spring and piston rod urge the syringe in a direction toward the injection site. 22. The method of claim 21, wherein when the syringe reaches an end of its travel within the device, the spring and piston rod cause the plunger to travel through the syringe to dispense the medicament through the needle. 23. The method of claim 8, wherein the syringe is viewable inside the auto-injector, and the method further comprises visually checking the syringe prior to the step of actuating the trigger mechanism. 24. The method of claim 6, wherein the syringe is viewable inside the auto-injector, and the method further comprises visually checking the syringe while performing the step of maintaining the delivery device against the injection site. 25. An ergoline derivative containing medicament comprising dihydroergotamine or a pharmaceutically acceptable salt thereof, wherein the medicament is disposed in an auto-injector device, the device comprising: a syringe containing the medicament; a hollow injection needle operably coupled to a distal end of the syringe; a dosing mechanism operably adjacent to a proximal end of the syringe; and a trigger mechanism operably coupled to the dosing mechanism, wherein the trigger mechanism, when actuated, causes the dosing mechanism to advance the syringe and the injection needle, and to discharge the medicament though the injection needle; and wherein the ergoline derivative is present in a concentration range of about 0.3 mg/mL to about 1.5 mg/mL. 26. The ergoline derivative containing medicament of claim 25, wherein the ergoline derivative is dihydroergotamine mesylate. 27. The ergoline derivative containing medicament of claim 25, wherein the concentration of the ergoline derivative is about 1 mg/mL. 28. The ergoline derivative containing medicament of claim 25, wherein the concentration of the ergoline derivative is about 1.5 mg/mL. 29. The ergoline derivative containing medicament of claim 25, wherein the concentration of the ergoline derivative is from about 0.5 to about 1.4 mg/mL. 30. The ergoline derivative containing medicament of claim 25, wherein the concentration of the ergoline derivative is from about 0.8 to about 1.2 mg/mL. 31. The ergoline derivative containing medicament of claim 25, wherein the auto-injector discharges a dose of between 0.5 mg to 3 mg of the ergoline derivative. 32. The ergoline derivative containing medicament of claim 25, wherein the medicament further comprises one or more tonicity adjusting agents, buffers, antioxidants, stabilizers, nonionic wetting or clarifying agents, and/or viscosity modifiers. 33. The ergoline derivative containing medicament of claim 25, wherein the medicament further comprises alcohol, glycerin, and water for injection. 34. The ergoline derivative containing medicament of claim 33, wherein the medicament further comprises a buffer and/or another pH adjusting agent. 35. The ergoline derivative containing medicament of claim 33, wherein the medicament further comprises sodium hydroxide or methane sulfonic acid. 36. The ergoline derivative containing medicament of claim 25, wherein the medicament comprises 1.0 mg dihydroergotamine mesylate, 49.0 mg ethanol, 150 mg glycerin, 800 mg water for injection, and a buffer comprising sodium hydroxide and/or methane sulfonic acid in an amount sufficient to attain the pH of the medicament to between 3.4 and 4.9.